Eculizumab (Soliris®) is approved for reimbursement by the HSE for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) through a Managed Access Process. This funding application process is in place solely to address long-term chronic funding issues for these indications and is not designed to assist hospitals in making acute financial decisions. Therefore, short-term in-patient management remains within the in-patient hospital governance.
For further information relating to the long-term funding of eculizumab for PNH and aHUS, please contact email@example.com.
Applications for individual reimbursement approval will only be considered from consultant haematologists or nephrologists.
The application forms for individual reimbursement approval can be found in the Related Files section below.